Teva Pharmaceutical Industries Ltd. (NYSE: TEVA TASE: TEVA) nowadays documented $3.7 billion profits for the initially quarter of 2022, down 8% from the corresponding quarter of 2021, and a little under the analysts’ consensus of $3.75 billion. Non-GAAP earnings for each share was $.55, assembly the analysts’ forecast.

Teva lower its 2022 earnings forecast from $15.6-16.2 billion to $15.4-16 billion and its Copaxone profits forecast from $850 million to $750 million.




Connected Articles or blog posts













In reaction, Teva’s share rate is down 2.58% in premarket buying and selling on the NYSE.

Teva president and CEO Kare Schultz explained, We are happy to continue resolving opioid-connected litigations with modern settlements in Florida and Rhode Island including the provision of lifesaving opioid treatment options and recovery medications for people who have to have them.”

He ongoing: “Although easing of Covid-19 connected restrictions has led to good momentum in our European enterprise, we are observing fluctuations of overseas exchange rates, and have as a result reduced our 2022 revenue outlook, whilst reaffirming our earnings and dollars move steerage.”

Posted by Globes, Israel small business information – en.globes.co.il – on May well 3, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.